Navigation Links
For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders' Opinions Indicate that AbbVie/Eisai's Humira Has the Best Clinical Profile Among Key Marketed Therapies
Date:6/3/2013

BURLINGTON, Mass., June 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that based on clinical data and the opinions of interviewed thought leaders, AbbVie/Eisai's Humira has the strongest clinical profile among key marketed products that treat psoriatic arthritis (PsA). None of the PsA therapies in development show advantages in efficacy over Humira, although UCB/Astellas's Cimzia has a clinical profile that is not differentiated from Humira based on thought leader opinion and clinical trial data.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

According to the DecisionBase 2013 report entitled Opportunity Remains for Novel Therapies That Address Rheumatologists' and Payers' Shared Views on Unmet Need in the TNF-Alpha-Inhibitor-Dominated PsA Market, while some other therapies in development hold promise, they have efficacy, safety and tolerability, and/or delivery disadvantages compared with Humira and Cimzia.

"The TNF-alpha inhibitors have set a high clinical standard that is challenging for emerging therapies to surpass," said Decision Resources Senior Analyst Bingnan Kang , Ph.D. "However, unmet needs exist for improvements in various efficacy, safety and tolerability, and delivery attributes. The PsA pipeline contains several agents with novel mechanisms of action that have the potential to fulfill some of these unmet needs."

The report also finds that physicians in the U.S. and Europe and managed care organization (MCO) pharmacy directors in the U.S. identify the need for new therapies with greater ability to halt progression of structural damage as a key unmet need. In addition, surveyed U.S. MCO pharmacy directors are particularly receptive to new PsA therapies that offer improved effect on signs and symptoms of arthritis over currently available therapies. Improvement of signs and symptoms and inhibition of progression of structural damage are two key treatment goals in the management of PsA.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
2. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
3. Forum Tackles the Rising Costs, Challenges and Diminished Outcomes Associated with Treating Obese Patients for Orthopaedic Conditions
4. Treating Poison Ivy Is A Snap! New Cortizone 10 Poison Ivy Relief Pads Launch Just In Time For Summer
5. Elektas Advanced Versa HD System to Begin Treating Cancer Patients at New Swiss Radiotherapy Clinic
6. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
7. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
8. Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
9. The Nairobi Hospital in Kenya Commences Treating Cancer with Advanced Radiotherapy Delivery Using Varian Equipment and Software
10. The Growing Cost of Aging: Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
11. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2019)... ... September 13, 2019 , ... St. Joseph’s Hospital, Robins ... the structural topping out of the St. Joseph’s Hospital patient tower expansion located ... new six-story patient tower that will house a two-story lobby, waiting and on-call ...
(Date:9/12/2019)... ... ... Stratosphere Networks will sponsor GRIN2B Foundation’s first cocktail reception fundraiser, ... at Found Kitchen and Social House in Evanston from 6 p.m. to 9 p.m. ... is a gene on the short arm of the 12th chromosome and is part ...
(Date:9/11/2019)... ... 12, 2019 , ... Understanding the Drug Supply Chain Security ... Sept. 26, 2019, 1:30-3:00 p.m. EDT, https://www.fdanews.com/understanding-the-dscsa , Need to comply ... clear on nuances of the guidelines regulating the drug supply chain? , ...
Breaking Medicine Technology:
(Date:9/18/2019)... SCOTCH PLAINS, N.J. (PRWEB) , ... September 18, ... ... Michael L. Scagnelli, DMD for the fourth consecutive year. Dr. Scagnelli specializes in ... Matawan-based practice was established in the 1940’s and has been delivering quality dental ...
(Date:9/17/2019)... ... 17, 2019 , ... Six Consulting Inc. (SIX) recently announced ... – specifically golden retrievers - through innovative cancer prevention medicine. A national survey ... out of five retrievers in the United States will die from a particular ...
(Date:9/17/2019)... ... ... Lubin Austermuehle, P.C. will be one of the sponsors of GRIN2B ... Found Kitchen and Social House in Evanston on Monday, October 7 from 6 p.m. ... rare condition that results from changes to the GRIN2B gene. The GRIN2B gene is ...
(Date:9/17/2019)... LYNDHURST, N.J. (PRWEB) , ... September 17, 2019 ... ... in a wide array of services, welcomes Dr. Yevgeniya (Jenny) Gartshteyn to their ... University Medical Center, where she previously held the Clinical Appointment of Assistant Professor ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful source of ... disease as he hopes to prevent anyone from having it and to help those ... Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to experience another ...
Breaking Medicine News(10 mins):